Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline


GT Biopharma, Inc. a targeted immunotherapies company.


Latest News

GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
Aug 20, 2020 • 8:00 EDT | Read More

GT Biopharma Advances To Dose Level 3 with TriKE(TM) FDA Phase I/II Clinical Trial
Aug 4, 2020 • 8:00 EDT | Read More


GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range